Author: [Generated AI] Date: October 2023 (updated for context) Abstract EZD-349 (Debio-0517) is an investigational, next-generation selective inhibitor of Cyclin-Dependent Kinase 9 (CDK9). Unlike earlier CDK inhibitors that caused widespread cell cycle arrest and toxicity, EZD-349 is designed to target the transcriptional arm of CDK9 function. By inhibiting CDK9/cyclin T1 (P-TEFb) complex, EZD-349 induces rapid depletion of short-lived anti-apoptotic proteins, notably MCL-1 and MYC, leading to selective apoptosis in tumor cells. This paper reviews the molecular mechanism, structure-activity relationship (SAR), preclinical pharmacokinetics (PK), efficacy in hematologic and solid tumor models, and the strategic rationale for its development as a first-in-class transcriptional cancer therapeutic. 1. Introduction Cyclin-Dependent Kinase 9 (CDK9) is a master regulator of transcriptional elongation. In complex with cyclin T1, it phosphorylates Serine 2 of the RNA Polymerase II (Pol II) C-terminal domain (CTD), releasing Pol II from promoter-proximal pausing. This process is critical for genes with short half-lives and high transcriptional rates, including MCL-1 (myeloid cell leukemia 1), MYC , NF-κB , and XIAP .
Primarily CYP3A4/5-mediated oxidation of the morpholino ring and glucuronidation. No reactive metabolites detected in GSH trapping assays. ezd-349